We need to adapt very tailored approaches and not consider BeNeLux as one market
In Conversation
What we can work to improve is the first step in a patient’s journey through the system. Currently, there are many barriers, and patients do not…
The reality of how cell and gene therapies and some of the other novel therapies will enter the market with an outcomes-based reimbursement model is going…
We are highly competitive in terms of patient recruitment. We have some of the highest numbers of patients in clinical trials per total number of patients…
With respiratory diseases, there is sometimes the erroneous perception that they are not as severe or urgent as other conditions. Nevertheless, COPD is already one of…
AbbVie is a remarkable organization, not only for its products but also for its focus on professional development, as well as its inclusive and diverse organizational…
We live in a time when value is becoming increasingly important. We feel that healthcare providers should continue to think about the bigger picture and overall…
A new set of rules is emerging in Mexican healthcare
Romania is the fastest growing [OTC] market in Europe, but it is still very traditional as the e-commerce boom has yet to come
My message is very simple: listen to yourself, get tested, and pass the message to others. Doctors also have a responsibility; we need to change the…
The challenge for orphan drugs is the price. It is not always easy to explain to the regulatory authorities that the value of such therapies should…
Romanian has one of the oldest populations in Europe, and this will translate into more patients with more needs.
